Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle.

Clovis: Shifting Toward Nuclear Medicine

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4

Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4

Clovis' shares dropped early in the day then rallied.

Why Clovis Oncology Stock Fell 10.5% on Monday

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

ADMA Biologics

Aditxt Inc

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn

Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.

Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study

Camber Energy

Hudson Capital

What you need to know about trading penny stocks in April The post Trading Penny Stocks & What You Need to Know in April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks & What You Need to Know in April

Gevo

Guardforce AI Co Ltd

Ring Energy

Short squeeze stocks to watch in April The post Top Penny Stocks To Buy Under $5? 4 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Under $5? 4 Short Squeeze Stocks To Watch Now

Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in the first-line ovarian setting.

Clovis Oncology: Forging A Fresh Perspective

Positive data regarding its lead drug boosted the company's shares.

Why Clovis Oncology Stock Skyrocketed 80% This Week

Clovis Oncology (CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. The post Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today appeared first on InvestorPlace.

Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today

Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free.

Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status

Dare Bioscience

First Wave BioPharma

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 31st, 2022

Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo. Based on the.

Why Clovis Oncology Stock Is Soaring Today

Shares of Clovis Oncology Inc. CLVS, -3.51% soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival when used as a maintenance treatment for women with ovarian cancer. The data comes from a double-blind, placebo-controlled, Phase 3 clinical trial that enrolled 538 women.

Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapy

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves PFS in First-line Maintenance Treatment in Women with Ovarian Cancer ...

Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286

Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286

Atossa Genetics

Eos Energy Enterprises

Which penny stocks are on your watchlist for next week? The post Hot Penny Stocks to Watch Next Week?

Hot Penny Stocks to Watch Next Week? 3 For Your List

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--LuMIERE TiP at SNMMI mid-Winter and ACNM meeting curtain raiser news release

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

News for Clovis Oncology Stock (CLVS)